ScreenerHero

SNDX Syndax Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · syndax.com
16.90USD-0.76%Mkt Cap: 1.50B $P/E: —

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap1.50B USD
Enterprise Value1.59B USD
Revenue (TTM)252.25M USD
Gross Profit165.38M USD
Net Income (TTM)-285.42M USD
Revenue/Share2.87 USD
Last Price16.90 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees298
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-20.34
PEG—
EV/EBITDA-8.17
EV/Revenue6.29
P/S6.10
P/B102.78
EPS (TTM)-2.52
EPS (Forward)-0.85
52W Range
12.9931% of range25.59
52W High25.59 USD
52W Low12.99 USD
Profitability
Gross Margin95.96%
Oper. Margin-54.95%
EBITDA Margin-76.97%
Profit Margin-165.60%
ROE-441.62%
ROA-53.88%
Growth
Revenue Growth91.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-322.98M USD
CapEx (TTM)187.00K USD
FCF Margin-59.50%
FCF Yield-10.02%
Net Debt35.12M USD
Net Debt/EBITDA-0.18
Balance Sheet
Debt/Equity5.34
Current Ratio6.77
Quick Ratio6.29
Book Value/Sh0.17 USD
Cash/Share6.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)37.55 USD
Upside (mean)+122.2%
Target Range26.00 USD – 57.00 USD
26.00+122.2% to mean57.00
# Analysts11
Ownership
Shares Out.88.61M
Float80.30M
Insiders1.69%
Institutions125.98%
Short Interest
Short Ratio16.2d
Short % Float23.54%
Short % Out.23.14%
Shares Short20.66M
Short (prev mo.)22.90M
Technical
SMA 5019.21 (-12.0%)
SMA 20020.86 (-19.0%)
Beta0.42
S&P 52W Chg16.45%
Avg Vol (30d)1.65M
Avg Vol (10d)1.74M
Technical Indicators
RSI (14)35.9
MACD-0.6411
MACD Signal-0.5725
MACD Hist.-0.0685
BB Upper19.69 USD
BB Middle18.13 USD
BB Lower16.58 USD
BB Width17.14%
ATR (14)0.8607 USD
Vol Ratio (20d)1.22x